People · Operator
Named in public records as an officer, director or promoter · active 2009–2017 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Capricor Therapeutics, Inc. | — | Biotechnology | Series B | $51.9M | $147.2M | 2013 |
| Pervasis Therapeutics Inc | — | Biotechnology | Series A | $10.0M | $361.6M | 2009 |
| Filmaka Inc | — | Other | Pre-Seed | $267K | $2.3M | 2009 |
Frank Litvack at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Frank Litvack on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amir Nashat | 1 | 14 |
| Robert S Langer | 1 | 14 |
| Joshua A. Kazam | 1 | 10 |
| David M. Tanen | 1 | 8 |
| George Dunbar | 1 | 5 |
| Arie S. Belldegrun | 1 | 5 |
| Joshua Kazam | 1 | 5 |
| Paul A. Mieyal | 1 | 4 |
| EDWIN M. KANIA | 1 | 3 |
| Robert F Higgins | 1 | 3 |
| Earl M Collier | 1 | 3 |
| Daron Evans | 1 | 3 |
| Pedro Granadillo | 1 | 3 |
| Elazer R Edelman | 1 | 2 |
| Richard B. Brewer | 1 | 2 |
| Peter M. Kash | 1 | 2 |
| Gregory Schafer | 1 | 2 |
| Andrew Hamer | 1 | 2 |
| Linda Marban | 1 | 2 |
| Gregory W. Schafer | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.